Retinitis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
Future and investigational therapies for retinitis include retinal prosthesis, bionic eyes, artificial vision, and retinal chips. A recently released apparatus, called Argus II, consists of a camera placed along a patients glasses' frame. The camera then sends information to a processing unit which is transferred to a microchip implanted in a patient's eye. Other therapies are focused on photoreceptor transplantation or activation of the induction of light sensitivity to retinal cells. | Future and investigational therapies for retinitis include retinal prosthesis, bionic eyes, artificial vision, and retinal chips. A recently released apparatus, called Argus II, consists of a camera placed along a patients glasses' frame. The camera then sends information to a processing unit which is transferred to a microchip implanted in a patient's eye. Other therapies are focused on photoreceptor transplantation or activation of the induction of light sensitivity to retinal cells.<ref name= "Retina Cyber">Retina Health Series. Retinal Prosthesis. American Society of Retina Specialists. https://www.asrs.org/patients/retinal-diseases/8/retinitis-pigmentosa-and-retinal-prosthesis. Accessed April 19th, 2016. </ref> | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
| Line 10: | Line 11: | ||
*Photoreceptor transplantation has also been an explored option. However studies have yet to show any viable benefits resulting from the procedure. | *Photoreceptor transplantation has also been an explored option. However studies have yet to show any viable benefits resulting from the procedure. | ||
*Studies have found that many retintis pigmentosa patients maintain ocular to brain connections even after photoreceptors die. Researchers therefore are attempting to develop options that will allow for the individual to bypass the photoreceptors by inducing the remaining cells to become light sensitive. These projects are termed optogenetic projects and have not yet entered further clinical investigation. | *Studies have found that many retintis pigmentosa patients maintain ocular to brain connections even after photoreceptors die. Researchers therefore are attempting to develop options that will allow for the individual to bypass the photoreceptors by inducing the remaining cells to become light sensitive. These projects are termed optogenetic projects and have not yet entered further clinical investigation. | ||
*Other methods include retinal prosthesis, bionic eyes, artificial vision, and retinal chips.<ref>Retina Health Series. Retinal Prosthesis. American Society of Retina Specialists. https://www.asrs.org/patients/retinal-diseases/8/retinitis-pigmentosa-and-retinal-prosthesis. Accessed April 19th, 2016. </ref> | *Other methods include retinal prosthesis, bionic eyes, artificial vision, and retinal chips.<ref name= "Retina Cyber">Retina Health Series. Retinal Prosthesis. American Society of Retina Specialists. https://www.asrs.org/patients/retinal-diseases/8/retinitis-pigmentosa-and-retinal-prosthesis. Accessed April 19th, 2016. </ref> | ||
*A recent device, Argus II, has recently been approved by the FDA for usage with RP patients. | *A recent device, Argus II, has recently been approved by the FDA for usage with RP patients. | ||
| Line 17: | Line 18: | ||
*Another investigational device, approved only in Europe, is the Alpha IMS retinal implant. | *Another investigational device, approved only in Europe, is the Alpha IMS retinal implant. | ||
*This device capture light rays and translates the rays to retinal neurons. | *This device capture light rays and translates the rays to retinal neurons. | ||
*Unfortunately the device requires alterations and improvements as visual improvement has only been recognized in a third of the implanted patient population.<ref>Retina Health Series. Retinal Prosthesis. American Society of Retina Specialists. https://www.asrs.org/patients/retinal-diseases/8/retinitis-pigmentosa-and-retinal-prosthesis. Accessed April 19th, 2016. </ref> | *Unfortunately the device requires alterations and improvements as visual improvement has only been recognized in a third of the implanted patient population.<ref name= "Retina Cyber">Retina Health Series. Retinal Prosthesis. American Society of Retina Specialists. https://www.asrs.org/patients/retinal-diseases/8/retinitis-pigmentosa-and-retinal-prosthesis. Accessed April 19th, 2016. </ref> | ||
Revision as of 14:12, 20 April 2016
|
Retinitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Retinitis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Retinitis future or investigational therapies |
|
Risk calculators and risk factors for Retinitis future or investigational therapies |
Overview
Future and investigational therapies for retinitis include retinal prosthesis, bionic eyes, artificial vision, and retinal chips. A recently released apparatus, called Argus II, consists of a camera placed along a patients glasses' frame. The camera then sends information to a processing unit which is transferred to a microchip implanted in a patient's eye. Other therapies are focused on photoreceptor transplantation or activation of the induction of light sensitivity to retinal cells.[1]
Future or Investigational Therapies
- Many of the efforts directed towards retinitis future and investigational therapies are aimed towards curing or preventing genetic retinal disorders.
- Research efforts have been focused on gene therapy in order to slow or prevent any progression of the disease.
- Photoreceptor transplantation has also been an explored option. However studies have yet to show any viable benefits resulting from the procedure.
- Studies have found that many retintis pigmentosa patients maintain ocular to brain connections even after photoreceptors die. Researchers therefore are attempting to develop options that will allow for the individual to bypass the photoreceptors by inducing the remaining cells to become light sensitive. These projects are termed optogenetic projects and have not yet entered further clinical investigation.
- Other methods include retinal prosthesis, bionic eyes, artificial vision, and retinal chips.[1]
- A recent device, Argus II, has recently been approved by the FDA for usage with RP patients.
- The device consists of a camera placed along a patients glasses' frame. The camera then sends information to a processing unit which is transferred to a microchip implanted in a patient's eye.
- Another investigational device, approved only in Europe, is the Alpha IMS retinal implant.
- This device capture light rays and translates the rays to retinal neurons.
- Unfortunately the device requires alterations and improvements as visual improvement has only been recognized in a third of the implanted patient population.[1]
References
- ↑ 1.0 1.1 1.2 Retina Health Series. Retinal Prosthesis. American Society of Retina Specialists. https://www.asrs.org/patients/retinal-diseases/8/retinitis-pigmentosa-and-retinal-prosthesis. Accessed April 19th, 2016.